novavax covid-19 - Search News

News

Novavax, FDA and Covid-19

Novavax says vaccine application still ‘approvable,’ despite FDA delay

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” requiring additional clinical study.

CNN International on MSN · 1d

FDA may ask Novavax to conduct additional trials of its Covid-19 vaccine to receive full approval

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 vaccine as a post-approval commitment, a source familiar with the matter told CNN.

Infectious Disease Advisor · 3h

Novavax COVID-19 Vaccine Moves Closer to Full FDA Approval

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Yahoo Finance3d

Novavax (NasdaqGS:NVAX) Announces Positive SHIELD-Utah Study Results

showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor's vaccine. This positive announcement aligns with a 17.8% increase in the company's share ...

Devdiscourse19h

Global Health Dynamics: From Ebola to COVID-19 Developments

A summary of current health news, including the disbanding of a U.S. Justice Department unit focusing on food and drug safety ...

2don MSN

FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports

(Reuters) -Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after ...

Zacks.com on MSN4d

Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Devdiscourse4d

Novavax Booster's Fate in Limbo: FDA Considers Approval Amid Controversy

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

Novavax's stock surges on 'good news' from Food and Drug Administration

Novavax’s protein-based vaccine is only available under a pandemic-era emergency-use authorization, and formal approval from ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results